1st Sep 2025 13:14
(Alliance News) - Abingdon Health PLC on Monday reported progress at Abingdon Health USA Inc, with five projects currently underway at its facilities in Madison, Wisconsin.
Shares in the York, England-based maker of lateral flow diagnostic tests rose 11% to 5.85 pence on Monday afternoon in London.
Abingdon Health reported that five new development projects have been inked and are now underway at its facilities in the US since April this year when operations commenced.
Whilst the company said details of projects remain confidential, they include work in a wide range of areas, such as the development of a duplex lateral flow to quantitatively measure the concentrations of a pharmaceutical product and its metabolite.
Other areas include the development of a lateral flow veterinary product for use initially in canine samples, and feasibility work with an unnamed US university to "evaluate novel nanoparticles for use in a lateral flow format."
Abingdon also noted project work tied to the development of a lateral flow test for infectious disease initially in bovine animals, and the development of a test for an infectious agent in animals and humans.
The company said the projects are being supported by colleagues at its UK facilities.
"These contract wins underline the importance of Abingdon Health's expansion of its CDMO offering in the US, extending its global reach to current and new US-based clients," said Abingdon Health.
The company also reported that phase two of its US facility expansion in Madison is currently underway, with plans commenced for "the installation of high-throughput manufacturing to enable the seamless transition of projects from development into manufacturing."
Executive Chair Chris Hand said: "These contract awards validate our decision to expand our CDMO operations into the USA and we anticipate further expansion in Madison, Wisconsin, as projects and products move through the development cycle. It is pleasing to see our US customers recognise the value of our comprehensive CDMO platform. We deliver end-to-end diagnostic solutions from initial concept through to market launch, and these contract wins illustrate strong confidence in our approach from US-based clients".
By Christopher Ward, Alliance News reporter
Comments and questions to [email protected]
Copyright 2025 Alliance News Ltd. All Rights Reserved.
Related Shares:
Abingdon Healt.